Bortezomib
Treatment for Multiple myeloma
Typical Dosage: 1.3 mg/m² IV or SC on days 1, 4, 8, 11 of a 21-day cycle
Effectiveness
88%
Safety Score
50%
Clinical Trials
591
Participants
25K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
1.3 mg/m² IV or SC on days 1, 4, 8, 11 of a 21-day cycle
Time to Effect
1-2 months
Treatment Duration
6-18 months
Evidence Quality
HIGHConfidence Score
96%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$80,000
Monitoring:$7,500
Side Effect Mgmt:$12,000
Total Annual:$99,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$120,000/QALY
QALYs Gained
1.8
Outcome-Based Costs
Cost per Responder
$124,375
Cost per Remission
$221,111
Comparison vs Thalidomide + Dexamethasone
Cost Difference
+$30,000/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Bortezomib Outcomes
for Multiple myeloma
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+80%
Remission Rate
+45%
Common Side Effects
Peripheral Neuropathy
+60%
Thrombocytopenia
+50%
Fatigue
+40%
Nausea/Diarrhea/Constipation
+40%
Herpes Zoster reactivation
+15%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
3 active trials recruiting for Bortezomib in Multiple myeloma
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
NCT06245629RECRUITING
100 participants
OBSERVATIONAL
Uppsala, Sweden
Started: Nov 24, 2024
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
NCT07085728NOT YET RECRUITINGPHASE2
74 participants
INTERVENTIONAL
Started: Aug 11, 2025
A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
NCT04268199RECRUITINGPHASE2
100 participants
INTERVENTIONAL
Calgary, Canada +1 more
Started: May 29, 2020
Completed Clinical Trials
10 completed trials for Bortezomib in Multiple myeloma
A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma
NCT02268890COMPLETEDPHASE4
18 participants
INTERVENTIONAL
Changhua, Taiwan +5 more
Started: Dec 1, 2014
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
NCT00153920COMPLETEDPHASE2
66 participants
INTERVENTIONAL
Atlanta, United States +5 more
Started: Dec 1, 2003
A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma
NCT01801436COMPLETEDPHASE3
14 participants
INTERVENTIONAL
Started: Dec 1, 2006
Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma
NCT00504634COMPLETEDPHASE2
8 participants
INTERVENTIONAL
Houston, United States
Started: Jan 1, 2004
An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma
NCT00431769COMPLETEDPHASE2
130 participants
INTERVENTIONAL
Graz, Austria +37 more
Started: Jun 1, 2006
A Retreatment Study With Bortezomib for Multiple Myeloma
NCT01030302COMPLETED
56 participants
OBSERVATIONAL
Started: Nov 1, 2008
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
NCT01090921COMPLETEDPHASE2
50 participants
INTERVENTIONAL
Little Rock, United States +10 more
Started: May 1, 2007
Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma
NCT00416208COMPLETEDPHASE3
154 participants
INTERVENTIONAL
Bamberg, Germany +36 more
Started: Oct 1, 2006
A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)
NCT00985959COMPLETEDPHASE1
101 participants
INTERVENTIONAL
Fukuoka, Japan +27 more
Started: Jul 1, 2008
Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma
NCT00652041COMPLETEDPHASE4
40 participants
INTERVENTIONAL
Murcia, Spain +4 more
Started: Jan 1, 2007
Showing 20 of 602 total trials